检索结果-南通市图书馆

宁波市COVID-19患者心理状况调查及影响因素分析

在线全文

学校读者我要写书评

暂无评论

医院管理论坛 2020年第4期37卷 115-117,8页

作者：邢红叶夏雅雄陈海燕王泓权诸建军中国科学院大学宁波华美医院中国科学院大学宁波生命与健康产业研究院宁波卫生职业技术学院宁波市康宁医院

目的调查宁波市COVID-19患者的心理状况并分析其影响因素,为患者的心理护理提供依据。方法于2020年1月25日―2020年2月12日,运用症状自评量表-90,对病区住院的42例COVID-19患者和同期40例的健康人进行调查,并采用单因素和逐步多元线性... 详细信息

目的调查宁波市COVID-19患者的心理状况并分析其影响因素,为患者的心理护理提供依据。方法于2020年1月25日―2020年2月12日,运用症状自评量表-90,对病区住院的42例COVID-19患者和同期40例的健康人进行调查,并采用单因素和逐步多元线性回归分析其影响因素。结果 COVID-19患者的心理状况有待提高,COVID-19组的SCL-90量表总均分明显高于对照组(p<0.05)。在所调查的9个维度中,COVID-19组的焦虑和抑郁的评分高于对照组,差异有统计学意义(p<0.05)。影响COVID-19患者心理状况的因素有临床分型、基础疾病和住院天数。其中主要影响因素是临床分型和住院天数。结论 COVID-19患者的心理健康状况比同期的对照组人群差,护士要针对患者可能出现的心理问题采取相应干预,增强患者治愈的信心。

关键词：新型冠状病毒病患者心理状况影响因素

在线全文

学校读者我要写书评

暂无评论

双相障碍躁狂发作患者反应抑制能力的研究

临床精神医学杂志 2019年第4期29卷 217-220页

作者：赵杰刘泱慧马雄英徐丹赖文涛黄世伟刘铁榜深圳市精神卫生中心深圳市康宁医院

目的:探讨双相障碍躁狂发作患者反应抑制能力。方法:对15例双相障碍躁狂发作患者(患者组)在执行Go/Nogo任务的同时进行事件相关电位(ERP)检测;采集前额区、中央区和顶叶区的N2和P3波幅;并与16位性别、年龄及受教育情况相匹配的健康对照... 详细信息

目的:探讨双相障碍躁狂发作患者反应抑制能力。方法:对15例双相障碍躁狂发作患者(患者组)在执行Go/Nogo任务的同时进行事件相关电位(ERP)检测;采集前额区、中央区和顶叶区的N2和P3波幅;并与16位性别、年龄及受教育情况相匹配的健康对照者(对照组)比较。结果:患者组前额区Go-N2波幅明显高于对照组(P<0.05);Nogo-N2波幅各脑区与对照组相比差异无统计学意义。前额区Go-P3波幅及前额区、中央区的Nogo-P3波幅显著低于对照组(P<0.05或P<0.01)。结论:双相障碍躁狂发作患者认知控制能力受损,体现在早期冲突觉察监控阶段以冲动性为主,认知控制加工的晚期阶段为认知资源投入不足。

关键词：双相障碍躁狂发作事件相关电位认知控制

在线全文

学校读者我要写书评

暂无评论

怡肾抗凝散穴位贴敷治疗肾病综合征60例

西部中医药 2014年第12期27卷 9-11页

作者：张继波覃娜莎熊有明邓晓蔚蒋背乐丁世永陈燕华桂林市中医医院广西桂林541002

目的:观察怡肾抗凝散穴位贴敷治疗肾病综合征的临床疗效。方法:将112例患者随机分为治疗组60例、对照组52例。对照组给予低盐、低脂、优质、低蛋白饮食,联合激素口服及环磷酰胺(CTX)治疗,治疗组在对照组治疗的基础上给予怡肾抗凝散穴位... 详细信息

目的:观察怡肾抗凝散穴位贴敷治疗肾病综合征的临床疗效。方法:将112例患者随机分为治疗组60例、对照组52例。对照组给予低盐、低脂、优质、低蛋白饮食,联合激素口服及环磷酰胺(CTX)治疗,治疗组在对照组治疗的基础上给予怡肾抗凝散穴位贴敷双侧肾俞、膀胱俞及膏肓俞。2组总疗程均为半年,治疗期间均未采用其他针对本病的治疗措施。观察2组治疗前、治疗后2个月、治疗后3个月及治疗后半年时血小板计数(Plt)、纤维蛋白原定量(Fib)、白蛋白(Alb)、总胆固醇(TC)及甘油三酯(TG)的变化情况。结果:总有效率治疗组为96.67%,对照组为88.46%,2组比较差异显著(P0.05);治疗后3个月比较,TC、TG无统计学意义(P>0.05),Alb、Plt、Fib有统计学意义(P<0.05);治疗后6个月比较,Alb、TC、TG、Plt及Fib均有统计学意义(P<0.05)。结论:怡肾抗凝散穴位贴敷能够改善患者的高凝倾向。

关键词：肾病综合征怡肾抗凝散穴位贴敷

Preserving cognitive function in patients with Alzheimer's disease:The Alzheimer's disease neuroprotection research initiative(ADNRI)

在线全文

学校读者我要写书评

暂无评论

Neuroprotection 2023年第2期1卷 84-98页

作者： Jie Liu Heleen van Beusekom Xian-Le Bu Gong Chen Paulo Henrique Rosado de Castro Xiaochun Chen Xiaowei Chen Andrew N.Clarkson Tracy D.Farr Yuhong Fu Jianping Jia Jukka Jolkkonen Woojin Scott Kim Paula Korhonen Shen Li Yajie Liang Guang-Hui Liu Guiyou Liu Yu-Hui Liu Tarja Malm Xiaobo Mao Joaquim Miguel Oliveira Mike M.Modo Pedro Ramos-Cabrer Karsten Ruscher Weihong Song Jun Wang Xuanyue Wang Yun Wang Haitao Wu Lize xiong Yi Yang Keqiang Ye Jin-Tai Yu Xin-Fu Zhou Marietta Zille Colin L.Masters Piotr Walczak Boltze Johannes Xunming Ji Yan-Jiang Wang Department of Neurology Daping HospitalThird Military Medical UniversityChongqingChina Chongqing Key Laboratory of Ageing and Brain Diseases ChongqingChina Division of Experimental Cardiology Department of CardiologyErasmus MCUniversity Medical CenterRotterdamThe Netherlands Institute of Brain and Intelligence Third Military Medical UniversityChongqingChina Guangdong-HongKong-Macao Institute of CNS Regeneration(GHMICR) Jinan UniversityGuangzhouGuangdongChina Institute of Biomedical Sciences Federal University of Rio de JaneiroRio de JaneiroRio de JaneiroBrazil Fujian Key Laboratory of Molecular Neurology Department of Neurology and GeriatricsFujian Institute of GeriatricsFujian Medical University Union HospitalInstitute of NeuroscienceFujian Medical UniversityFuzhouFujianChina Guangyang Bay Laboratory Chongqing Institute for Brain and IntelligenceChongqingChina Center for Excellence in Brain Science and Intelligence Technology Chinese Academy of SciencesShanghaiChina Department of Anatomy Brain Health Research Centre and Brain Research New ZealandUniversity of OtagoDunedinNew Zealand School of Life Sciences University of NottinghamNottinghamUK Brain and Mind Centre&School of Medical Sciences The University of SydneySydneyNew South WalesAustralia Innovation Center for Neurological Disorders and Department of Neurology Xuanwu HospitalNational Clinical Research Center for Geriatric DiseasesCapital Medical UniversityBeijingChina A.I.Virtanen Institute for Molecular Sciences University of Eastern FinlandKuopioFinland Department of Neurology and Psychiatry Beijing Shijitan HospitalCapital Medical UniversityBeijingChina Department of Diagnostic Radiology and Nuclear Medicine University of Maryland School of MedicineBaltimoreMarylandUSA University of Chinese Academy of Sciences BeijingChina State Key Laboratory of Membrane Biology Institute of ZoologyChinese Academy of SciencesBeijingChina Beijing Institute of Brain Disorders Laboratory of Brain DisordersMinistry of Sci

The global trend toward aging populations has resulted in an increase in the occurrence of Alzheimer's disease(AD)and associated socioeconomic *** metabolism of amyloid-β(Aβ)has been proposed as a significant pathomechanism in AD,supported by results of recent clinical trials using anti-Aβ***,the cognitive benefits of the current treatments are *** etiology of AD is multifactorial,encompassing Aβand tau accumulation,neuroinflammation,demyelination,vascular dysfunction,and comorbidities,which collectively lead to widespread neurodegeneration in the brain and cognitive ***,solely removing Aβfrom the brain may be insufficient to combat neurodegeneration and preserve *** attain effective treatment for AD,it is necessary to(1)conduct extensive research on various mechanisms that cause neurodegeneration,including advances in neuroimaging techniques for earlier detection and a more precise characterization of molecular events at scales ranging from cellular to the full system level;(2)identify neuroprotective intervention targets against different neurodegeneration mechanisms;and(3)discover novel and optimal combinations of neuroprotective intervention strategies to maintain cognitive function in AD *** Alzheimer's Disease Neuroprotection Research Initiative's objective is to facilitate coordinated,multidisciplinary efforts to develop systemic neuroprotective strategies to combat *** aim is to achieve mitigation of the full spectrum of pathological processes underlying AD,with the goal of halting or even reversing cognitive decline.

关键词： Alzheimer's disease early intervention neural regeneration neuroprotection systematic perspective

六字整合心理行为法用于慢性失眠症的疗效观察

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

临床医药实践 2023年第10期32卷 723-725页

作者：兰胜作邹果果温凉熊典樟王阳刘世中陈思颖何花平欧雷刚邱广文宜春市第三人民医院江西宜春336000 漳浦康宁医院福建漳浦363200

目的:验证六字整合心理行为法应用于慢性失眠症的疗效。方法:将符合入组标准的慢性失眠症患者分别归入观察组(n=43)和对照组(n=43)。观察组采用六字整合心理行为法,对照组给予一般的睡眠卫生指导。两组患者均停用所有安眠药进行35 d的... 详细信息

目的:验证六字整合心理行为法应用于慢性失眠症的疗效。方法:将符合入组标准的慢性失眠症患者分别归入观察组(n=43)和对照组(n=43)。观察组采用六字整合心理行为法,对照组给予一般的睡眠卫生指导。两组患者均停用所有安眠药进行35 d的门诊指导及观察;通过门诊复诊或手机微信复诊方式,于入组时和入组后3 d,7 d,14 d,21 d,28 d,35 d用失眠严重程度指数(ISI)评估两组疗效,以入组后脱落的病例数统计两组依从性。结果:入组14 d内(包括第14天)两组ISI比较差异无统计学意义(P>0.05);入组后21 d,28 d和35 d,观察组的ISI明显优于对照组,差异有统计学意义(P0.05)。结论:应用六字整合心理行为法21 d后能明显改善慢性失眠者的睡眠。

关键词：六字整合心理行为法慢性失眠症疗效